
Steven Eichberg Elected Chair of LRF Board of Directors
Eichberg, a Board member since 2019, assumed his new duties from outgoing Chair Michael Werner, whose four-year term concluded on June 30.

Eichberg, a Board member since 2019, assumed his new duties from outgoing Chair Michael Werner, whose four-year term concluded on June 30.
The Lymphoma Research Foundation (LRF) welcomes three new members to their elite Scientific Advisory Board (SAB). The new members represent distinct specialties that will contribute to the international impact of the Lymphoma Research Foundation.
LRF Spokesperson and acclaimed journalist Lisa Guerrero kicks off nationwide cheeseboard challenge to drive lymphoma awareness.

Selinexor (XPOVIO, Karyopharm Therapeutics, Inc.) is a single-agent oral tablet approved for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma (FL), after at least 2 lines of systemic therapy.

Tazemetostat (TAZVERIK), an EZH2 inhibitor, and the EZH2 Mutation Test were granted approval for adult patients with relapsed or refractory follicular lymphoma (FL).

The new class of LRF Scholars is pursuing research projects covering a diverse range of lymphoma subtypes with a goal to improve patient outcomes.

Dr. Kara Kelly is helping to build the bridge between AYA, and pediatric and adult oncology fields to bring attention to this underserved population and improve patient care.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is impacting women globally—leaving many questions for both patients and providers.

Being a socially responsible company helps businesses “do good” while building credibility among its customers and employees.

Dear Friends, As I celebrate lymphoma survivors and their loved ones this month – National Cancer Survivors Month – and the incredible progress in lymphoma research that has made a month like this possible, I am also reminded that our…